EcoDrugPlus

Platelet Activating Factor Receptor

Ensembl ID : ENSACLG00000015282
Gene Symbol: PTAFR
3 Cross references
213 Possible Orthologues:

Platelet Derived Growth Factor Receptor Alpha

Ensembl ID : ENSACLG00000015927
Gene Symbol: PDGFRA
3 Cross references
204 Possible Orthologues:

Platelet Derived Growth Factor Subunit B

Ensembl ID : ENSACLG00000007857
Gene Symbol: PDGFB
2 Cross references
192 Possible Orthologues:

Platelet-Activating Factor Receptor-Like

Ensembl ID : ENSACLG00000015287
Gene Symbol: LOC113012139
2 Cross references
210 Possible Orthologues:

Platelet-Derived Growth Factor Receptor Beta-Like

Ensembl ID : ENSACLG00000001648
Gene Symbol: LOC113030276
2 Cross references
174 Possible Orthologues:

Platelet-Derived Growth Factor Receptor, Beta Polypeptide

Ensembl ID : ENSACLG00000009008
Gene Symbol: PDGFRB
1 Cross references
199 Possible Orthologues:

Polo Like Kinase 1

Ensembl ID : ENSACLG00000004225
Gene Symbol: PLK1
4 Cross references
187 Possible Orthologues:

Poly (Adp-Ribose) Polymerase 2

Ensembl ID : ENSACLG00000005390
Gene Symbol: PARP2
1 Cross references
186 Possible Orthologues:

Poly(Adp-Ribose) Polymerase Family Member 3

Ensembl ID : ENSACLG00000023617
Gene Symbol: PARP3
3 Cross references
199 Possible Orthologues:

Porcupine O-Acyltransferase

Ensembl ID : ENSACLG00000004168
Gene Symbol: PORCN
3 Cross references
197 Possible Orthologues:

Potassium Calcium-Activated Channel Subfamily M Alpha 1

Ensembl ID : ENSACLG00000013694
Gene Symbol: KCNMA1
3 Cross references
227 Possible Orthologues:

Potassium Calcium-Activated Channel Subfamily M Alpha 1

Ensembl ID : ENSACLG00000006888
Gene Symbol: KCNMA1
1 Cross references
244 Possible Orthologues:


PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains. Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).

PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains.

Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).